vida: extract claims from 2026-04-xx-jmcp-glp1-medicaid-persistence-tirzepatide-vs-semaglutide

- Source: inbox/queue/2026-04-xx-jmcp-glp1-medicaid-persistence-tirzepatide-vs-semaglutide.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -13,7 +13,7 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
 reweave_edges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
 sourced_from: ["inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md"]
-related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access"]
+related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level"]
 ---
 
 # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
@@ -46,3 +46,10 @@ Among patients with diagnosed conditions showing clear clinical benefit, uptake
 **Source:** HR Brew December 2025, 9amHealth partnership announcements
 
 The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.
+
+
+## Supporting Evidence
+
+**Source:** JMCP 2026 Medicaid persistence study
+
+Medicaid population data shows 60.8% 6-month persistence with cost as primary discontinuation driver. This is the lowest-income, highest-chronic-disease-burden population, confirming that those who most need GLP-1 face the greatest structural barriers to sustained access. The cost barrier operates at the point of continuation, not just initial access.

domains/health/illinois-mhpaea-2024-rule-enforcement-creates-natural-experiment-for-outcome-data-evaluation.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2025-07-01-illinois-idoi-company-bulletin-2025-10-mhpaea-2024-rule-enforcement.md
 scope: experimental
 sourcer: Illinois Department of Insurance
-related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance"]
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance", "illinois-mhpaea-2024-rule-enforcement-creates-natural-experiment-for-outcome-data-evaluation", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement"]
 ---
 
 # Illinois's enforcement of the paused 2024 MHPAEA Final Rule creates a natural experiment for whether outcome data evaluation can change insurer reimbursement practices for mental health providers
 
 On May 15, 2025, HHS announced it would not enforce amendments to MHPAEA regulations from the 2024 Final Rule, specifically the outcome data evaluation requirements designed to detect reimbursement rate discrimination. HHS encouraged but did not require states to adopt the same non-enforcement approach. Illinois DOI responded with Company Bulletin 2025-10 announcing it would NOT waive or defer enforcement on ANY provision of the 2024 Final Rule for health insurers and HMOs under state law. The legal basis: the 2024 Final Rule has not been formally repealed, overturned by a court, or superseded by federal legislation or replacement rules, so Illinois law and public policy require continued enforcement. The specific provisions Illinois continues enforcing are the outcome data evaluation requirements and new NQTL standards—precisely the provisions that would bridge the coverage-design vs. reimbursement-rate gap in the two-level access problem. Illinois DOI has contracted with Health Services Advisory Group (HSAG) to conduct a Mental Health Parity Analysis of all HealthChoice Illinois and Youth Care health plans, assessing processes for MHPAEA compliance including the 2024 rule's outcome data evaluation requirements. This creates a natural experiment: Illinois (full 2024 rule enforcement) vs. states following the federal pause. If Illinois shows measurable improvement in mental health access metrics over 2-3 years, it would provide the strongest evidence yet that outcome-based enforcement can address the two-level access problem. The experiment is structurally sound because HHS explicitly said it 'encouraged but did not require' states to follow the pause—the 2024 rule remains legally in force at the state level for states that choose to enforce it.
+
+
+## Extending Evidence
+
+**Source:** Kennedy Forum Mental Health Parity Index, April 2026
+
+New York State committed to examining in-depth Mental Health Parity Index metrics for its 11 million commercially insured citizens (with support from NY Community Trust), creating a second natural experiment alongside Illinois. Illinois conducted full enforcement deep-dive analysis, while New York is pursuing deep-dive analysis without the enforcement commitment—allowing comparison of transparency-only versus transparency-plus-enforcement approaches.

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -6,7 +6,7 @@ confidence: experimental
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
 related_claims: ["divergence-glp1-economics-chronic-cost-vs-low-persistence"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap"]
 reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17"]
 supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs"]
 sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
@@ -88,3 +88,10 @@ Truveta ISPOR 2025 data confirms income >$80,000 predicts lower discontinuation
 **Source:** JAMA Network Open 2025 (PMC11786232)
 
 Income >$80K predicts lower discontinuation rates in this JAMA study, providing direct evidence that financial access barriers affect not just initiation but persistence. The income gradient operates throughout the treatment lifecycle, not just at the prescription decision point.
+
+
+## Supporting Evidence
+
+**Source:** JMCP 2026 Medicaid persistence study
+
+JMCP 2026 Medicaid study directly documents that cost is the #1 discontinuation driver, accounting for nearly half of discontinuations. This moves the claim from 'suggesting affordability' to 'proving affordability' as the binding constraint. The study explicitly measured discontinuation reasons rather than inferring from income correlations.

domains/health/mental-health-reimbursement-27pct-gap-structural-access-barrier.md

@@ -10,27 +10,9 @@ agent: vida
 sourced_from: health/2026-04-30-rti-kennedy-forum-mental-health-reimbursement-27pct-gap.md
 scope: structural
 sourcer: RTI International / The Kennedy Forum
-supports:
-- mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates
-- the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access
-- mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement
-- Colorado HB 25-1002 establishes the first state-level outcomes data testing authority for behavioral health parity enforcement, creating a potential natural experiment for access-metric enforcement
-- Mental Health Parity Index
-- The Mental Health Parity Index documents that 43 states have structural access disparities in commercial insurance driven by below-Medicare reimbursement rates, not just coverage design failures
-related:
-- mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates
-- the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access
-- mental-health-reimbursement-27pct-gap-structural-access-barrier
-- state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity
-- mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement
-- Colorado HB 25-1002
-- Reimbursement benchmarking tools are the necessary but missing infrastructure for outcome-based MHPAEA enforcement
-reweave_edges:
-- Colorado HB 25-1002|related|2026-05-02
-- Colorado HB 25-1002 establishes the first state-level outcomes data testing authority for behavioral health parity enforcement, creating a potential natural experiment for access-metric enforcement|supports|2026-05-02
-- Mental Health Parity Index|supports|2026-05-02
-- The Mental Health Parity Index documents that 43 states have structural access disparities in commercial insurance driven by below-Medicare reimbursement rates, not just coverage design failures|supports|2026-05-02
-- Reimbursement benchmarking tools are the necessary but missing infrastructure for outcome-based MHPAEA enforcement|related|2026-05-02
+supports: ["mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement", "Colorado HB 25-1002 establishes the first state-level outcomes data testing authority for behavioral health parity enforcement, creating a potential natural experiment for access-metric enforcement", "Mental Health Parity Index", "The Mental Health Parity Index documents that 43 states have structural access disparities in commercial insurance driven by below-Medicare reimbursement rates, not just coverage design failures"]
+related: ["mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement", "Colorado HB 25-1002", "Reimbursement benchmarking tools are the necessary but missing infrastructure for outcome-based MHPAEA enforcement", "mental-health-parity-index-documents-43-states-structural-access-disparities-driven-by-below-medicare-reimbursement", "reimbursement-benchmarking-tools-necessary-missing-infrastructure-outcome-based-mhpaea-enforcement"]
+reweave_edges: ["Colorado HB 25-1002|related|2026-05-02", "Colorado HB 25-1002 establishes the first state-level outcomes data testing authority for behavioral health parity enforcement, creating a potential natural experiment for access-metric enforcement|supports|2026-05-02", "Mental Health Parity Index|supports|2026-05-02", "The Mental Health Parity Index documents that 43 states have structural access disparities in commercial insurance driven by below-Medicare reimbursement rates, not just coverage design failures|supports|2026-05-02", "Reimbursement benchmarking tools are the necessary but missing infrastructure for outcome-based MHPAEA enforcement|related|2026-05-02"]
 ---
 
 # Mental health providers are reimbursed 27.1% less than medical/surgical providers for comparable services creating a structural access barrier that MHPAEA enforcement cannot address because the law requires comparable processes not comparable rates
@@ -49,4 +31,10 @@ Colorado HB 25-1002's outcomes data testing authority creates a potential enforc
 
 **Source:** Mental Health Parity Index, April 2026
 
-Mental Health Parity Index (April 2026) provides first national tool measuring access disparities at state/county level using reimbursement benchmarks, confirming majority of MH/SUD clinicians paid below Medicare rates. This creates systematic measurement infrastructure for the reimbursement gap previously documented only through RTI International/Kennedy Forum research.
+Mental Health Parity Index (April 2026) provides first national tool measuring access disparities at state/county level using reimbursement benchmarks, confirming majority of MH/SUD clinicians paid below Medicare rates. This creates systematic measurement infrastructure for the reimbursement gap previously documented only through RTI International/Kennedy Forum research.
+
+## Extending Evidence
+
+**Source:** Kennedy Forum Mental Health Parity Index, April 2026
+
+Mental Health Parity Index reveals reimbursement gap is not a single 27.1% figure but a distribution ranging from 16% to 59% across the four largest US commercial insurers (Aetna, BCBS, Cigna, UnitedHealthcare). ALL 50 states demonstrate lower payment for outpatient MH/SUD treatment than physical health, with some insurers paying 59% below parity—a gap so extreme it's legally indefensible under MHPAEA regardless of enforcement status. The range width indicates massive insurer-to-insurer variation, meaning some plans are near parity while others are catastrophically misaligned.

domains/health/mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-04-14-mhpaea-three-level-access-problem-synthesis.md
 scope: structural
 sourcer: Vida (synthesis)
 supports: ["mental-health-reimbursement-27pct-gap-structural-access-barrier"]
-related: ["SDOH-interventions-show-strong-roi-but-adoption-stalls-because-z-code-documentation-remains-below-3-percent-and-no-operational-infrastructure-connects-screening-to-action", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance"]
+related: ["SDOH-interventions-show-strong-roi-but-adoption-stalls-because-z-code-documentation-remains-below-3-percent-and-no-operational-infrastructure-connects-screening-to-action", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement", "colorado-hb25-1002-establishes-outcomes-data-testing-authority-for-behavioral-health-parity-enforcement"]
 ---
 
 # MHPAEA enforcement has evolved to three levels — coverage design (level 1), access metrics (level 1.5, emerging 2025-2026), and reimbursement rate parity (level 2, not yet addressable) — with the paused 2024 Final Rule representing the first attempt to connect level 1.5 measurement to level 2 remediation
 
 MHPAEA enforcement has historically operated at Level 1 (coverage design parity): ensuring mental health benefits exist with comparable terms to medical/surgical benefits through NQTL analysis. Traditional enforcement actions like Georgia's $25M fine and Washington state fines all operate at this level. However, 2025-2026 saw the emergence of Level 1.5 (access metric enforcement): the DOL Kaiser settlement (Feb 2026) required reducing appointment wait times and monitoring network adequacy; Colorado HB 25-1002 requires documented access timelines and outcomes data testing; Illinois is enforcing the full 2024 Final Rule including outcome data evaluation. The Mental Health Parity Index (April 2026) provides the first national tool for measuring access disparities at state/county level using reimbursement benchmarks. But Level 2 (reimbursement rate parity) remains unaddressed: the 27.1% mental health provider reimbursement gap vs. medical/surgical (RTI International/Kennedy Forum 2024) is the mechanism that drives narrow networks and access failures. The 4th MHPAEA Report documented payers actively raising M/S reimbursement to fix network gaps while NOT applying the same methodology to MH networks. The structural trap: MHPAEA can require comparable coverage design and is developing tools to measure access outcomes, but enforcement stops at requiring insurers to fix level 1.5 failures without identifying the level 2 mechanism. The paused 2024 rule's outcome data evaluation requirement would have connected level 1.5 measurement to level 2 causation by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. Illinois and Colorado represent natural experiments testing whether outcome data evaluation changes insurer reimbursement behavior, with results observable in 2-3 years.
+
+
+## Extending Evidence
+
+**Source:** Kennedy Forum / NY Community Trust / NY DFS, April 2026
+
+New York becomes the second state after Illinois to commit to deep-dive parity analysis using the Mental Health Parity Index for level 2 (reimbursement rate) evidence. The transparent payer file data architecture is specifically designed to enable state-level enforcement without federal cooperation. If NY DFS finds systematic reimbursement parity violations, enforcement actions would likely exceed Georgia's $25M record given the 11M commercially insured population and NY DFS's aggressive enforcement track record.

domains/health/semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md

@@ -5,16 +5,9 @@ description: "Within the GLP-1 class, semaglutide shows 2.5x better one-year per
 confidence: likely
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-related:
-- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
-reweave_edges:
-- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|related|2026-04-09
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09
-sourced_from:
-- inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md
+related: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism"]
+reweave_edges: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|related|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09"]
+sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
 ---
 
 # Semaglutide achieves 47 percent one-year persistence versus 19 percent for liraglutide showing drug-specific adherence variation of 2.5x
@@ -47,4 +40,10 @@ Relevant Notes:
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 
 Topics:
-- domains/health/_map
+- domains/health/_map
+
+## Extending Evidence
+
+**Source:** JMCP 2026 Medicaid study
+
+Tirzepatide shows 71.7% 6-month persistence vs semaglutide 56.5% in Medicaid population — a 15 percentage point gap. This is larger than the previously documented semaglutide-liraglutide gap and occurs in the most cost-constrained population, suggesting the persistence advantage may be driven by superior tolerability/efficacy rather than selection bias alone. However, 6-month data only — 12-month durability unknown.

domains/health/trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance.md

@@ -54,4 +54,10 @@ The Kaiser settlement creates a nuanced enforcement posture under Trump DOL: out
 
 **Source:** Synthesis of 2024 Final Rule provisions
 
-The paused 2024 rule's outcome data evaluation requirement was the specific mechanism designed to connect Level 1.5 measurement (access metrics) to Level 2 remediation (reimbursement rates) by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. The pause removes this connection mechanism.
+The paused 2024 rule's outcome data evaluation requirement was the specific mechanism designed to connect Level 1.5 measurement (access metrics) to Level 2 remediation (reimbursement rates) by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. The pause removes this connection mechanism.
+
+## Extending Evidence
+
+**Source:** Kennedy Forum Mental Health Parity Index, April 2026
+
+As of April 2026, federal health officials confirmed they will not enforce the parity law (Trump administration pause of 2024 MHPAEA Final Rule enforcement). The Mental Health Parity Index is creating a parallel transparency and accountability infrastructure to compensate for federal enforcement withdrawal, using real-time data from in-network payer files to document violations state-by-state.

inbox/archive/health/2026-04-14-kennedy-forum-mhparity-index-national-launch-full-data.md

@@ -7,10 +7,13 @@ date: 2026-04-14
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: high
 tags: [mental-health, parity, MHPAEA, reimbursement, access, insurance, Kennedy-Forum]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-30-ny-state-mental-health-parity-index-11m-commercially-insured.md

@@ -7,10 +7,13 @@ date: 2026-04-30
 domain: health
 secondary_domains: []
 format: news-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: medium
 tags: [mental-health, parity, MHPAEA, New-York, DFS, state-enforcement, Kennedy-Forum]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-xx-jmcp-glp1-medicaid-persistence-tirzepatide-vs-semaglutide.md

@@ -7,10 +7,13 @@ date: 2026-03-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: medium
 tags: [GLP-1, Medicaid, persistence, adherence, semaglutide, tirzepatide, real-world-evidence, cost-barriers]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content